In PBMCs of patients with acute coronary syndrome, in-vitro simvastatin 10 μM was able to increase the percentage of CD4 + CD25 + FoxP3+ regulatory T cells to total CD4+ cells [40]. Here, FOXP3 is linked to acute coronary syndrome.